Glucosil for treating and inhibiting recurrent yeast infections
Glucosil combines poly d-glucosamine and silver nanoparticles to treat and prevent recurrent yeast infections by disrupting biofilm formation and preventing resistance development.
Overview
Glucosil is an innovative solution designed to treat and inhibit recurrent yeast infections by leveraging its unique biostatic properties. The compound utilizes poly d-glucosamine combined with micro-particle size silver to attract bacteria and yeasts to its amine groups. The mucoadhesive property of glucosamine ensures that threats adhere to these receptors, where the silver component disrupts the cell wall proteins of the pathogens. This action not only eradicates existing biofilms but also prevents the formation of new ones, thereby inhibiting recurrence and resistance development.
Technical specifications
Key features:
- Biostatic properties: Attracts and binds bacteria and yeasts, disrupting their ability to form biofilms.
- Mucoadhesive action: Ensures prolonged contact with vaginal cell walls for effective treatment.
- Silver nanoparticle integration: Causes cell wall disintegration and inhibits DNA from forming resistance proteins.
- Proven efficacy: Validated against candida albicans and E. coli, including multi-drug resistant strains.
Technology readiness level
Glucosil is currently at a Technology Readiness Level (TRL) of 4, indicating that it has been validated in laboratory settings. Future validation plans include replicating successful research protocols to further establish its efficacy and safety.
About Chitozan Health LLC
Chitozan Health LLC is a biotechnology research firm that develops antimicrobial solutions utilizing patented silver-chitosan technology [1][3][5]. Their core innovation, marketed as Silver Shell or Glucosil, incorporates chitosan and silver particles to create durable, effective antimicrobial barriers for various applications [1][5][8]. By leveraging the biostatic properties of chitosan, the company produces textile finishes and topical gels that are designed to combat pathogens, including bacteria, fungi, and viruses, while minimizing the use of silver and maintaining safety standards [1][5][8]. This research is supported by NIH NIAID funding and focuses on managing infections, such as those related to Pseudomonas aeruginosa in cystic fibrosis, as well as providing broad-spectrum protection in healthcare and consumer settings [1][5][7].
These products serve a range of stakeholders, from industrial partners in textile manufacturing and sustainable packaging to healthcare providers and individual consumers in need of advanced wound and burn care [1][4][7][8]. The company's technology addresses critical challenges such as antimicrobial resistance, infection control, and the environmental impact of synthetic materials [1][4][8]. Through rigorous independent laboratory testing, their treatments have demonstrated significant efficacy in reducing pathogen populations and sustaining performance even after multiple commercial wash cycles [1][5]. With a focus on sustainable, naturally derived materials, Chitozan Health aims to provide safer, more effective alternatives for infection mitigation across multiple sectors [1][7].
delivered to your inbox.